

<b>EDGAR Submission Header Summary</b>	
Submission Form Type	6-K
XBRL	NonXBRLSubmission
Period of Report	12-08-2021
Filer	Nanobiotix S.A.
CIK	0001760854
CCC	xxxxxxx
Exchanges	NASD
Co-Registrants	
Submission Contact	
Contact Phone Number	
Documents	2

<b>Documents</b>	
6-K	a52546483.htm
Description	Nanobiotix S.A. 6-K
EX-99.1	a52546483ex99_1.htm
Description	Exhibit 99.1

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

**Date of Report: 12/08/2021**

**Commission File Number: 001-39777**

**Nanobiotix S.A.**

**(Exact Name of Registrant as Specified in its Charter)**

**60 Rue de Wattignies  
75012 Paris, France  
(Address of principal executive office)**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

**EXHIBIT INDEX**

**Exhibit      Title**

[99.1](#)            [Press Release, dated December 08, 2021](#)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**PORTER NOVELLI**  
(Agency)

By: /s/ Emily Papp

Emily Papp  
Senior Account Executive

**NANOBIOTIX S.A.**  
(Registrant)

By: /s/ Bart Van Rhijn

Bart Van Rhijn  
Chief Financial Officer

## Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital

*In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorité des Marchés Financiers (French Financial Markets Authority)*

PARIS--(BUSINESS WIRE)--December 8, 2021--Regulatory News:

Nanobiotix (Paris:NANO) (NASDAQ:NBTX):

Market: Euronext Paris / Nasdaq  
Euronext Compartment: B  
ISIN code: FR0011341205  
Nasdaq: NBTX  
Bloomberg: NANO:FP  
Reuters: NANO.PA  
Website: www.nanobiotix.com

Date	Number of Shares Outstanding	Total number of voting rights	
		Total voting rights, gross (1)	Total voting rights, net (2)
November 30, 2021	34,825,872	36,003,389	35,985,166

*(1) The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.*

*(2) The total number of net (or "exercisable at a Shareholders' Meeting") voting rights is calculated without taking into account shares for which voting rights have been suspended. It is released in order to ensure that the public is properly informed, in accordance with the AMF recommendation of July 17, 2007.*

\*\*\*

**About NANOBIOTIX:** <http://www.nanobiotix.com>

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity.

The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life. Incorporated in 2003, Nanobiotix is headquartered in Paris, France. The company also has subsidiaries in Cambridge, Massachusetts (United States), France, Spain, and Germany. Nanobiotix has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market in New York City since December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and biodistribution; and 3) disorders of the central nervous system.

The company's resources are primarily devoted to the development of its lead product candidate—NBTXR3—which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify®.

For more information about Nanobiotix, visit us at <http://www.nanobiotix.com> or follow us on LinkedIn and Twitter.

## Contacts

*Nanobiotix*

### **Nanobiotix Communications**

Brandon Owens  
VP, Communications  
+1 (617) 852-4835  
[contact@nanobiotix.com](mailto:contact@nanobiotix.com)

### **Nanobiotix Investor Relations**

Kate McNeil  
SVP, Investor Relations  
+1 (609) 678-7388  
[investors@nanobiotix.com](mailto:investors@nanobiotix.com)

*Media Relations*

### **France – Ulysse Communication**

Pierre-Louis Germain  
+33 (0) 6 64 79 97 51  
[plgermain@ulyse-communication.com](mailto:plgermain@ulyse-communication.com)

### **US – Porter Novelli**

Dan Childs  
+1 (781) 888-5106  
[dan.childs@porternovelli.com](mailto:dan.childs@porternovelli.com)